<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02330926</url>
  </required_header>
  <id_info>
    <org_study_id>MENAC-2013-05</org_study_id>
    <secondary_id>2013-002282-19</secondary_id>
    <nct_id>NCT02330926</nct_id>
  </id_info>
  <brief_title>Multimodal Intervention for Cachexia in Advanced Cancer Patients Undergoing Chemotherapy</brief_title>
  <acronym>MENAC</acronym>
  <official_title>A Randomised, Open-label Trial of a Multimodal Intervention (Exercise, Nutrition and Antiinflammatory Medication) Plus Standard Care Versus Standard Care Alone to Prevent/Attenuate Cachexia in Advanced Cancer Patients Undergoing Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Norwegian University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>St. Olavs Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cantonal Hospital of St. Gallen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ottawa Regional Cancer Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jewish General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cross Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Beatson West of Scotland Cancer Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Queen Margaret Hospital, Dunfermline</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cancer Research UK Edinburgh Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Malteser Krankenhaus Seliger Gerhardt</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tumor Biology Center Freiburg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tumor Zentrum Aarau</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chelsea and Westminister Hospital NHS</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cedars-Sinai Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guy's and St Thomas' NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>NHS Forth Valley</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Norwegian University of Science and Technology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cancer cachexia is a multi-factorial syndrome defined by an ongoing loss of skeletal muscle&#xD;
      mass (with or without loss of fat mass) that cannot be fully reversed by conventional&#xD;
      nutritional support and leads to progressive functional impairment.&#xD;
&#xD;
      There is an urgency for improving management, but there is no consensus on the optimal&#xD;
      treatment for cancer cachexia. Several single therapies for cancer cachexia have been&#xD;
      examined in clinical trials, with disappointing overall results. As multiple factors are&#xD;
      responsible for the development of cachexia, it has been argued that optimal cachexia&#xD;
      interventions should target all components: multimodal therapy for a multimodal problem.&#xD;
&#xD;
      The overall aim of this study is to early prevent the development of cachexia rather than&#xD;
      treatment late in the disease trajectory. From a patient perspective a short term effect will&#xD;
      be to improve physical and psychological function, to reduce symptom burden and to improve&#xD;
      survival. In other words live a longer and better life during and after chemotherapy. Direct&#xD;
      effects of the cachexia intervention are expected to be reduction of weight and muscle loss,&#xD;
      and improved physical activity and quality of life.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 2015</start_date>
  <completion_date type="Anticipated">January 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change in body weight</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>change in muscle mass</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in physical activity</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Cachexia</condition>
  <condition>Neoplasms</condition>
  <arm_group>
    <arm_group_label>multimodal intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>standard care plus multimodal intervention consisting of nutritional supplements and advice, home-based self-assisted exercise program, and anti-inflammatory medication (ibuprofen)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>standard palliative care</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>standard care</intervention_name>
    <arm_group_label>multimodal intervention</arm_group_label>
    <arm_group_label>standard care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>nutritional supplements and advice</intervention_name>
    <arm_group_label>multimodal intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>home-based self-assisted exercise program</intervention_name>
    <arm_group_label>multimodal intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibuprofen</intervention_name>
    <arm_group_label>multimodal intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of lung cancer, pancreatic cancer or cholangiocarcinoma where the diagnosis&#xD;
             is based on histological, radiological or multidisciplinary team (MDT) evaluation&#xD;
&#xD;
          -  non-small cell lung cancer (stage III or IV), pancreatic adenocarcinoma (stage III or&#xD;
             IV), due to commence first or second line anticancer treatment (defined as&#xD;
             chemotherapy, chemo-radiotherapy, targeted therapy or immunotherapy)&#xD;
&#xD;
          -  staging CT within 4 weeks of commencement of anti-cancer therapy (in patients where&#xD;
             staging CT is out-with this period, further CT scanning will be undertaken. PETCT's&#xD;
             are also appropriate)&#xD;
&#xD;
          -  completed all other baseline assessments within one week prior to first course of&#xD;
             anti-cancer treatment&#xD;
&#xD;
          -  written informed consent&#xD;
&#xD;
          -  able to comply with trial interventions (in the opinion of referring clinician) e.g.&#xD;
             willing and able to do light exercise and take oral nutritional supplements as well as&#xD;
             no major contraindications against ibuprofen.&#xD;
&#xD;
          -  Karnofsky Performance Status &gt;70&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Neuro-endocrine pancreatic cancer&#xD;
&#xD;
          -  Creatinine clearance &lt;30ml/min&#xD;
&#xD;
          -  Receiving parenteral nutrition or enteral nutrition via feeding tube&#xD;
&#xD;
          -  receiving neo-adjuvant anti-cancer therapy&#xD;
&#xD;
          -  BMI &gt;30 kg/m2&#xD;
&#xD;
          -  Use of appetite stimulants or anabolic/anti-catabolic agents (such as megestrol&#xD;
             acetate, progestational agents, marijuana growth hormone, dronabinol, or other&#xD;
             anabolic agent) within 30 days prior to study baseline&#xD;
&#xD;
          -  Concomitant steroid (&gt;10mg/d prednisolone or equivalent) treatment for less than three&#xD;
             months prior to inclusion (inhaled, optical or pulsed oral steroids (up to 10 days&#xD;
             use) are permitted)&#xD;
&#xD;
          -  Concomitant long term (&gt;1 week) nonsteroidal anti-inflammatory drugs (NSAID) or&#xD;
             aspirin treatment&#xD;
&#xD;
          -  pregnancy, breast-feeding or of child bearing potential (that is not postmenopausal or&#xD;
             permanently sterilised) age and not using adequate contraception (oral, injected,&#xD;
             implanted or hormonal methods of contraception, intrauterine device and barrier&#xD;
             method)&#xD;
&#xD;
          -  Concomitant anti-coagulant treatment (e.g. warfarin or heparin)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stein Kaasa, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>European Palliative Care Research Centre (PRC), Department of Cancer Research and Molecular Medicine, Faculty of Medicine, NTNU, Trondheim, Norway</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marie Fallon, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh, UK</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Trude R Balstad, PhD</last_name>
    <email>trude.r.balstad@ntnu.no</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tora S Solheim, MD PhD</last_name>
    <email>tora.l.skeidsvoll@ntnu.no</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>CA 90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kim Haesoo</last_name>
      <email>Haesoo.kim@cshs.org</email>
    </contact>
    <contact_backup>
      <last_name>Jar-Yee Liu</last_name>
      <email>Jar-Yee.Liu@cshs.org</email>
    </contact_backup>
    <investigator>
      <last_name>Andrew Hendifar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CA4 Brampton Civic Hospital</name>
      <address>
        <city>Brampton</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Achal Sharma</last_name>
      <email>Achal.sharma@williamoslerhs.ca</email>
    </contact>
    <contact_backup>
      <last_name>Deepanjali Kaushik</last_name>
      <email>Deepanjali.kaushik@williamoslerhs.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Parneet Cheema, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cross Cancer Insitute</name>
      <address>
        <city>Edmonton</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meri-Jo Thompson</last_name>
      <email>methompson@toh.ca</email>
    </contact>
    <investigator>
      <last_name>Quincy Chu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jewish General Hospital</name>
      <address>
        <city>Montréal</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ottawa Regional Cancer Centre</name>
      <address>
        <city>Ottawa</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meri-Jo Thompson</last_name>
      <email>methompson@toh.ca</email>
    </contact>
    <investigator>
      <last_name>Thimothy Asmis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Bonn</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Uta Wolber</last_name>
      <email>Uta.Wolber@ukbonn.de</email>
    </contact>
    <investigator>
      <last_name>Lukas Radbruch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Asta Bye, PhD</last_name>
      <email>astbye@ous-hf.no</email>
    </contact>
    <contact_backup>
      <email>menac@stolav.no</email>
    </contact_backup>
    <investigator>
      <last_name>Nina Aass, MD, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Olavs Hospital</name>
      <address>
        <city>Trondheim</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trude R Balstad, PhD</last_name>
      <email>trude.r.balstad@ntnu.no</email>
    </contact>
    <contact_backup>
      <last_name>Gunnhild Jakobsen, PhD</last_name>
      <email>menac@stolav.no</email>
    </contact_backup>
    <investigator>
      <last_name>Tora S Solheim, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tumor Zentrum</name>
      <address>
        <city>Aarau</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cantonal Hospital</name>
      <address>
        <city>St. Gallen</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>NHS Forth Valley</name>
      <address>
        <city>Larbert</city>
        <state>Falkirk</state>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Brogan</last_name>
      <email>menac@soton.ac.uk</email>
    </contact>
    <contact_backup>
      <last_name>Darran Ball</last_name>
      <email>menac@soton.ac.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Nicola Steele</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Queen Margaret Hospital</name>
      <address>
        <city>Dunfermline</city>
        <state>Fife</state>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacke Madden</last_name>
      <email>menac@ac.soton.uk</email>
    </contact>
    <contact_backup>
      <last_name>Darran Ball</last_name>
      <email>menac@ac.soton.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Joanna Bowden</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Llandough Hospital</name>
      <address>
        <city>Cardiff</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jackie Madden</last_name>
      <email>menac@soton.ac.uk</email>
    </contact>
    <contact_backup>
      <last_name>Darran Ball</last_name>
      <email>menac@soton.ac.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Anthony Byrne, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Edinburgh Cancer Centre</name>
      <address>
        <city>Edinburgh</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kim Sladdin</last_name>
      <email>menac@ac.soton.uk</email>
    </contact>
    <contact_backup>
      <last_name>Darran Ball</last_name>
      <email>menac@ac.soton.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Barry Laird, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beatson West of Scotland Cancer Centre</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jackie Madden</last_name>
      <email>menac@soton.ac.uk</email>
    </contact>
    <contact_backup>
      <last_name>Darran Ball</last_name>
      <email>menac@soton.ac.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Janet Graham</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chelsea and Westminister Hospital NHS</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena Noval</last_name>
      <email>menac@soton.ac.uk</email>
    </contact>
    <contact_backup>
      <last_name>Darran Ball</last_name>
      <email>menac@soton.ac.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Ruth Caulkin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guys and St Thomas</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jackie Madden</last_name>
      <email>menac@ac.soton.uk</email>
    </contact>
    <contact_backup>
      <last_name>Darran Ball</last_name>
      <email>menac@soton.ac.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Nickolas Gough, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Germany</country>
    <country>Norway</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Solheim TS, Laird BJA, Balstad TR, Bye A, Stene G, Baracos V, Strasser F, Griffiths G, Maddocks M, Fallon M, Kaasa S, Fearon K. Cancer cachexia: rationale for the MENAC (Multimodal-Exercise, Nutrition and Anti-inflammatory medication for Cachexia) trial. BMJ Support Palliat Care. 2018 Sep;8(3):258-265. doi: 10.1136/bmjspcare-2017-001440. Epub 2018 Feb 9. Review.</citation>
    <PMID>29440149</PMID>
  </reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>December 31, 2014</study_first_submitted>
  <study_first_submitted_qc>January 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 5, 2015</study_first_posted>
  <last_update_submitted>March 3, 2021</last_update_submitted>
  <last_update_submitted_qc>March 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Combined modality treatment</keyword>
  <keyword>Diet therapy</keyword>
  <keyword>Exercise therapy</keyword>
  <keyword>Ibuprofen</keyword>
  <keyword>Dietary supplements</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wasting Syndrome</mesh_term>
    <mesh_term>Cachexia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ibuprofen</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

